Varocto, Inc. was founded in 2014 as an ophthalmological imaging company. Using Optical Coherence Tomography (OCT), the company’s technology is able to provide angiographic images of the human retina. This imaging technology is especially well-suited for the clinical diagnosis of Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD). The technology is rapid, noninvasive, and provides significant advantages over current methods of retinal angiography. The technology was developed by AMI-USC in partnership with the Translational Imaging Center at USC under the direction of Professor Scott Fraser. The company was financed through a private equity investment.